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Background and purpose: Elevated levels of amyloid deposition aswell as whitematter damage are thought to be
risk factors for Alzheimer Disease (AD). Here we examined whether qualitative ratings of white matter damage
predicted cognitive impairment beyond measures of amyloid.
Materials and methods: The study examined 397 cognitively normal, 51 very mildly demented, and 11 mildly
demented individuals aged 42–90 (mean 68.5). Participants obtained a T2-weighted scan as well as a positron
emission tomography scan using 11[C] Pittsburgh Compound B. Periventricular white matter hyperintensities
(PVWMHs) and deepwhitematter hyperintensities (DWMHs)weremeasured on each T2 scan using the Fazekas
rating scale. The effects of amyloid deposition andwhitematter damagewere assessed using logistic regressions.
Results: Levels of amyloid deposition (ps b 0.01), as well as ratings of PVWMH (p b 0.01) and DWMH (p b 0.05)
discriminated between cognitively normal and demented individuals.
Conclusions: The amount of amyloid deposition and white matter damage independently predicts cognitive im-
pairment. This suggests a diagnostic utility of qualitative white matter scales in addition to measuring amyloid
levels.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer disease (AD) is a rapidly expanding health crisis affecting
over 26million people, with the prevalence expected to rise dramatical-
ly (Brookmeyer et al., 2007). Research examining AD biomarkers sug-
gests a rise in underlying pathology a decade or more before the onset
of dementia, and continuing throughout the early stages of the disease
(Bateman et al., 2012; Benzinger et al., 2013; Jack et al., 2010). There
is need to translate such biomarkers from a laboratory setting into a
clinical environment to assist with disease diagnosis and prognosis.
The hallmarks of AD pathology are the formation of amyloid beta
(Aβ) plaques and the aggregation of tau into neuroﬁbrillary tangles
(NFTs) (Braak and Braak, 1995; Hardy and Higgins, 1992). Early eleva-
tions in such pathology are subsequently followed by hypometabolism,
structural atrophy, and cognitive impairment (Bateman et al., 2012;chool of Medicine, 660 South
314 362 1558.
. This is an open access article underBenzinger et al., 2013; Jack et al., 2010). Atrophy of cortical and subcor-
tical graymatter has long been noted in AD (e.g. Fox et al., 1996; Gordon
et al., 2013; Scheltens et al., 1992). Less attention has been paid towhite
matter damage and declines tied to AD disease progression.
Early work with computed tomography (CT) images noted in-
creased incidence of white matter leukoaraiosis in individuals with AD
(Blennow et al., 1991; Rezek et al., 1987). Similar results were found
with the introduction of magnetic resonance imaging (MRI) (Barber
et al., 1999; Fazekas et al., 1987). In this initial work the most common
way to characterize white matter damage was to use semi-quantitative
scales (Fazekas et al., 1987; Kapeller et al., 2003; Scheltens et al., 1995)
to grade the severity of white matter hyperintensities (WMHs) on
T2-weighted or ﬂuid-attenuated inversion recovery (FLAIR) scans. At a
pathological level, the tissue suffering from WMHs demonstrates the
loss of myelin and gliosis. Higher ratings on these scales are associated
with both cognitive decline (Debette et al., 2007; Schmidt et al., 2005;
van Straaten et al., 2008) and cortical atrophy (Capizzano, 2004;
Schmidt et al., 2005). In general there is a rising interest on the clinical
importance of WMH across diseases (Debette and Markus, 2010).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Population demographics. Values represent the mean, standard deviation, and then range
of the values.
CDR = 0 CDR = 0.5 CDR = 1
Number 397 51 11
Gender 36% male*+ 61% male 91% male
Age 67.1 (9.5)*+
42–89
76.8 (7.1)
60–90
78.1 (5.5)
67–90
MMSE 29.2 (1.1)*+
25–30
26.7 (2.5)X
20–30
22.3 (3.8)
16–30
MCBP_raw .14 (.23)*+
−.26–1.47
.44 (.35)
−.04–1.22
.65 (.36)
−.01–1.06
MCBP .32 (.43)*+
−.21–2.41
.91 (.69)
.01–2.57
1.32 (.66)
.12–1.92
PiB+_raw 21%*+ 65% 82%
PiB+ 21%*+ 71% 82%
MCBP_raw = mean cortical binding potential. MCBP = partial-volume adjusted mean
cortical binding potential. PiB+_raw = percentage PiB+ using unadjusted MCBP cutoff
of .18. PiB = percentage PiB+ using partial-volume corrected MCBP cutoff of .23.
* p b .05 between CDR 0 and CDR 0.5.
+ p b .05 between CDR 0 and CDR 1.
X p b .05 between CDR .5 and 1.
247B.A. Gordon et al. / NeuroImage: Clinical 8 (2015) 246–252The relationship betweenWMHand amyloid is complex and has not
been fully evaluated, although there are suggestions that both con-
tribute to cognitive impairment (Provenzano et al., 2013).Whitematter
damage may be both a downstream result of elevated Aβ levels, as well
as a marker of comorbid pathology (e.g. cardiovascular disease). Aβ
leads to oxidative damage and the formation of free radicals (Hensley
et al., 1994; Park et al., 2004; Thomas et al., 1996), and the administra-
tion of Aβ damages oligodendrocytes in vitro (Roth et al., 2005) and
in vivo (Jantaratnotai et al., 2003). Conversely damage to myelin re-
leases iron molecules that promote Aβ oligomerization (Bartzokis
et al., 2007; Bartzokis, 2011). An initial rise in Aβwould damage white
matter, which in turn would elevate Aβ levels, subsequently leading
to more white matter damage in a continuing cyclical process. Alter-
natively, white matter lesions from a secondary process (e.g. head
injury) may release iron, and initiate or accelerate the pathological
inﬂuences of Aβ on white matter. Such results can been seen in
the literature as circulating levels of Aβ are associated with WMH
(Gurol et al., 2006), and baseline levels of white matter lesions pre-
dict an accelerated accumulation of amyloid over time (Grimmer
et al., 2012).
Using semi-quantitative scales,whitematter lesions have often been
seen in individuals with compromised cardiovascular systems (Breteler
et al., 1994; Longstreth et al., 1996). Consistent with these results, there
has been a suggestion that AD may have a larger vascular component
than often recognized (Bartzokis, 2011; de la Torre, 2010; Launer,
2002). Indeed, in epidemiological studies, cardiovascular risk factors
such as diabetes or stroke lead to increased risk of AD (Luchsinger
et al., 2001). Damage to the cardiovascular system, such as a thickening
and sclerosis of arteries, may lead to an impaired drainage of mole-
cules such as Aβ (Huang et al., 2010). Due to their potentially related
nature, it is of interest to know whether the incidence of WMHs pro-
vides any diagnostic value above and beyond levels of Aβ pathology
in the brain.
White matter damage in the brain can be assessed using visual rat-
ings of WMH, quantiﬁcation of WMH volumes, and using diffusion ten-
sor imaging (DTI). While there is a clear utility to quantifying damage
using DTI and WMH volumetric measurement, visual rating scales are
an easily obtained radiological measure available across both research
and clinical settings. Herewe examine the relationships betweenAβde-
position, white matter damage, and dementia in a population of cogni-
tively normal, very mildly demented, and mildly demented individuals.
Based upon prior work in the literature, we hypothesize that more se-
vere semi-quantitative ratings of white matter damage will be related
to an impaired cognitive status.
2. Materials and methods
2.1. Study population
Middle aged and older adults were drawn from studies on aging and
dementia conducted through the Knight Alzheimer3s Disease Research
Center (ADRC) at Washington University in St. Louis. Based upon the
Clinical Dementia Rating (CDR) Scale (Morris, 1993) participants were
classiﬁed as cognitively normal (CDR = 0, n = 397, female = 256),
very mildly demented (CDR= 0.5, n = 51, female = 20), or mildly de-
mented (CDR= 1, n = 11, female = 1). Individuals with dementia are
also given a primary diagnosis by the examining neurologist. Using
these diagnoses individuals whose dementia was thought to be from a
non-Alzheimer cause (e.g. Lewy bodies, vascular dementia, depression)
were excluded from all analyses. The population ranged in age from
42 to 90, with a mean age of 68.5 years (Table 1). All participants
underwent a structural imaging session as well as positron emission
tomography (PET) to estimate amyloid deposition using 11[C] Pittsburgh
Compound B (PiB) (Klunk et al., 2004). All procedures where approved
byWashingtonUniversity3s institutional reviewboard andwere conduct-
ed in accordance with the Declaration of Helsinki.2.2. T2 protocol
High-resolution T2-weighted images were acquired on a Siemens
Trio 3 T scanner (SiemensMedical Systems, Iselin, NJ). Scan parameters
were: repetition time (TR) of 3200ms, echo time (TE) of 455, ﬂip angle
(FA) = 120°, with a 256 × 256 ﬁeld of view, and a 1 mm isotropic
resolution.
2.3. Clinical ratings
A trained neurologist (S.N.), blind to clinical diagnosis, examined the
T2-weighted images. The presence and severities of WMH were rated
using criteria outlined by Fazekas et al. (1987). Brieﬂy, periventricular
hyperintensities (PVWMHs) were rated as follows: 0 absence of
WMH; 1 “caps” or pencil-thin linings; 2 “halos”; and 3 irregular PVH
extending into deep white matter. Ratings of WMH in the deep white
matter (DWMH) were rated as follows: 0 absence of WMH, 1 solitary
foci; 2 the beginning aggregation of foci; and 3 large conﬂuent areas of
WMH. Examples are given in Fig. 1 and distributions of scores across
the three clinical groups are presented in Fig. 2. A subset of 29 individ-
uals was rated two times to establish reliability. The intraclass correla-
tion was .91 for periventricular ratings and .98 for deep white matter
ratings.
2.4. PiB imaging
Participants underwent a 60-minute dynamic scanwith PiB. Binding
potentials were calculated for multiple regions of interest (ROIs) de-
rived from Freesurfer using a cerebellar reference for regions-of-
interest. The raw time–activity curve for each region was adjusted by
a CSF dilution factor in a given voxel to yield partial volume corrected
data. An average across both left and right lateral orbitofrontal, interior
parietal, precuneus, rostral middle frontal, superior frontal, superior
temporal, and middle temporal ROIs yielded the mean cortical binding
potential (MCBP). All analyses used MCBP as a continuous variable.
As supplementary analyses, individuals were also codiﬁed as PiB pos-
itive or negative using a previously published value fromour center of un-
adjusted MCBP of 0.18 (Vlassenko et al., 2011). A second supplementary
analysis deﬁned the cutoff on partial-volume corrected MCBP data de-
rived from a ROC analysis comparing 212 cognitively normal individuals
to 59 CDR = 0.5 with an AD diagnosis. Using this approach the partial-
volume adjusted MCBP cutoff was determined to be .23, which was the
point that maximized the Youden Index (sensitivity + speciﬁcity− 1).
Distributions of partial-volume adjusted MCBP scores are presented in
Fig. 1. The ﬁgure shows individuals with A) no white matter damage, B) minimal periventricular white matter hyperintensities (PVWMHs) and deep white matter hyperintensities
(DWMHs), C) minimal PVWMHs but moderate DWMHs, D) moderate PVWHMs but minimal DWMHs, and E) severe PWHHs and DWMHs. Arrows highlight areas of white matter
damage.
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plemental Fig. 1.2.5. Measures of vascular health
We assessed the presence (1) or absence (0) of a history of hyper-
tension, heart attack, atrial ﬁbrillation, angioplasty, bypass surgery,
congestive heart failure, stroke, transient ischemic attack, and diabetes.
Height information and weight information were used to calculate BMI,
and coded for the presence or absence of obesity (BMI N 30). An ag-
gregate vascular risk factor was created by summing the scores of all
variables (possible range of 0–10) (actual range 0–6,mean 1.14,median
0). Across the entire sample there was a modest bivariate correlation
between a history of hypertension and PVWMH (r = .21, p b .0001)
and DWMH (r= .19, p b .0001) scores. Similarly the summary vascular
risk score signiﬁcantly correlated with both PVWMH (r= .17, p b .001)Fig. 2. Distribution of Fazekas scores for periventricular white matter hyperintensities (PVandDWMH(r= .16, p b .001). Unsurprisingly, a history of hypertension
and the vascular risk were highly correlated (r = .65, p b .00001).2.6. Effects of WMH and MCBP on cognition
Initial stepwise logistic regressions examined the effects of age, gen-
der, MCBP and a measure of white matter damage (either DWMH or
PVWMH). Models additionally allowed for an interaction between
white matter damage and MCBP to enter the model. Models tested
whether each predictor discriminated between cognitively normal indi-
viduals and demented individuals (combined CDR= 0.5 and 1). For the
gender variable women were coded as 0 and males as 1.
For each predictor the exponentiation of the beta coefﬁcient
(Exp(B)) indicates the odds ratio, or the change in relative log odds of
being in the tested group (e.g. CDR N 0) relative to the reference group
(e.g. CDR = 0) with a one unit change in the predictor. If the oddsWMHs) and deep white matter hyperintensities (DWMHs) across the three groups.
Fig. 3. Distributions of partial volume adjusted mean cortical binding potentials in cognitively normal (left) and demented (right) participants.
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predictor indicates a greater likelihood to be in the test group (e.g.
CDR N 0). If the odds ratio is b1, then the outcome is more likely to
be in the reference group (e.g. CDR = 0). For all analyses an increase
in the Exp(B) indicated greater cognitive impairment.
An additional way to examine the data was presented by calculating
the area under the curve (AUC) values from receiver operating charac-
teristics (ROC) curves separating cognitively normal individuals from
demented individuals. The ﬁrst model looked at the AUC only using
the initial covariates of age and gender. A second set of models exam-
ined the AUC using the covariates and then one predictor of interest
(i.e. MCBP, PVWMH, or DWMH). A ﬁnal set of models examined the
AUC when using covariates, MCBP, and either of the WMH measures.
Signiﬁcant changes in the AUC were assessed using DeLong3s test for
correlated ROC curves (DeLong et al., 1988) using a package implement-
ed in R (Robin et al., 2011).
Exploratory multinomial logistic regressions compared predictors
across all three groups. These analyses test whether each predictor of
interest (e.g. WMH, MCBP, age) signiﬁcantly differs between each
level of the dependent variable (CDR 0, 0.5, and 1). The structure
of these models was set to be identical to that revealed by the step-
wise logistic regression comparing cognitively normal to all de-
mented individuals.Table 2
Logistic regression examining the effects of white matter hyperintensities on cognition.
B Std. error Sig. Exp(B)
CDR 0 vs. CDR N 0 Intercept −9.16 1.67 .00001
Age .07 .02 .001 1.08
Gender 1.25 .34 .001 3.50
MCBP 1.30 .25 .00001 3.68
PVWMH .71 .19 .001 2.03
CDR 0 vs. CDR N 0 Intercept −10.44 1.64 .00001
Age .10 .02 .001 1.10
Gender 1.28 .34 .001 3.60
MCBP 1.29 .25 .00001 3.63
DWMH .42 .20 .036 1.52
MCBP = mean cortical binding potential; PVWMH = periventricular white matter
hyperintensity; DWMH= deep white matter hyperintensity.3. Results
3.1. Demographics
Demographics are presented in Table 1. There were baseline demo-
graphic differences between groups. There weremoremales in the CDR
0.5 (χ2 = 12.2, p b .0005) and CDR 1 (χ2 = 14.1, p b .0005) groups rel-
ative to CDR0. Compared to CDR 0 individuals, CDR0.5 individualswere
older (t = 7.0, p b .000001), had lower MMSE (−13.2, p b .000001),
greaterMCBP (t= 8.3, p b .00001), and a greater proportion of PiB+ in-
dividuals (χ2 = 45.2, p b .000001). Similarly relative to CDR 0 individ-
uals those with a CDR = 1 were older (t = 3.81, p b .001), had lower
MMSE (−18.9, p b .000001), greater MCBP 1 (7.4, p b .00001), and a
greater proportion of PiB+ individuals (χ2 = 22.7, p b .000005). CDR
1 individuals had lowerMMSE than CDR 0.5 individuals but did not sig-
niﬁcantly differ in any other way. As age and gender differed across
groups, they were considered as covariates when examining the effects
of WMH and amyloid on cognition.3.2. Effects of WMH and MCBP on cognition
The full results from the initial logistic regressions are presented in
Table 2. For all signiﬁcant effects, an increase in the odds ratio for the
measure of interest (e.g. age) indicated a greater likelihood of being cog-
nitively impaired.When examiningMCBP alongside PVWMH therewas
a signiﬁcant effect of age (Exp(B) 1.08, p b 0.001), gender (Exp(B) 3.50,
p b 0.001), MCBP (Exp(B) 3.68, p b 0.0001), and PVWHM (Exp(B) 2.03,
p b 0.01). When examining MCBP alongside DWMH there was a signif-
icant effect of age (Exp(B) 1.10, p b 0.001), gender (Exp(B) 3.60,
p b 0.001), MCBP (Exp(B) 3.63, p b 0.0001), and DWMH (Exp(B) 1.52,
p b 0.05). The interaction terms between MCBP and WMH were
non-signiﬁcant and not entered into either model. The signiﬁcant ef-
fect ofWMHon cognition can clearly be seen in Fig. 2, which depicts the
distribution of the Fazekas scores for periventricular white matter
hyperintensities (PVWMHs) and deep white matter hyperintensities
(DWMHs) across the three groups. Treating amyloid deposition as a di-
chotomous PiB+/− variable did not substantively change the models
(Supplementary Tables 1 and 2).
It is possible to gain a bit more understanding of the size of these ef-
fects by calculating the ROC AUC. When predicting dementia status
solely from the covariates (age and gender) the AUC is .831. When
adding MCBP to the model the AUC signiﬁcantly increased to .875
(z =−2.41, p b .05). There were non-signiﬁcant increases in the AUC
when adding only the PVWMH (AUC.849, z = −1.34, p = .18) or
DWMH (AUC = .836, z = −.5242, p = .60) to the covariate only
Table 3
Effects of periventricular white matter hyperintensities. For all comparisons cognitively
normal individuals are used as the reference group.
B Std. error Sig. Exp(B)
CDR 0 vs. 0.5 Intercept −9.19 1.75 .00001
Age .075 .02 .002 1.13
Gender 1.07 .35 .002 5.81
MCBP 1.19 .26 .00001 5.53
PVWMH .67 .20 .001 2.86
CDR 0 vs. 1 Intercept −12.68 3.69 .00001
Age .07 .05 .181 1.07
Gender 2.92 1.09 .007 18.53
MCBP 2.01 .52 .0001 7.49
PVWMH .98 .36 .006 1.95
CDR 0.5 vs. 1 Intercept −3.49 3.70 .347
Age −.01 .05 .826 .99
Gender 1.85 1.10 .091 6.36
MCBP .82 .51 .108 2.27
PVWMH .32 .35 .366 1.37
MCBP = mean cortical binding potential; PVWMH = periventricular white matter
hyperintensity; Exp(B) = exponentiation of B coefﬁcient, or the odds ratio.
Table 5
Logistic regression examining the effects of white matter hyperintensities on cognition
controlling for hypertension.
B Std. error Sig. Exp(B)
CDR 0 vs. CDR N 0 Intercept −9.06 1.70 .00001
Age .07 .02 .003 1.07
Gender 1.24 .34 .001 3.46
Hypertension .26 .35 .46 1.30
MCBP 1.32 .26 .00001 3.76
PVWMH .69 1.70 .001 2.00
CDR 0 vs. CDR N 0 Intercept −10.32 1.66 .00001
Age .09 .02 .001 1.10
Gender 1.26 .34 .001 3.53
Hypertension .30 .35 .380 1.36
MCBP 1.32 .25 .00001 3.74
DWMH .39 .20 .050 1.48
250 B.A. Gordon et al. / NeuroImage: Clinical 8 (2015) 246–252model. Including both MCBP and PVWMH led to an AUC of .886
(z = −2.63, p b .01) and AUC of .876 when using MCBP DWMH
(z = −2.26, p = b .05). While signiﬁcant relative to the covariate
only models, the increase in AUC in the models combining MCBP
and WMH was not signiﬁcantly different from models considering
MCBP alone. Combined with the results from the logistic regres-
sions, this suggests only modest effects of WMH above amyloid
deposition.
The full results from the multinomial logistic regressions are present-
ed in Tables 3 and 4. These results are quite similar to the logistic regres-
sions above when comparing cognitively normal individuals to either
group of demented individuals. When contrasting those with very mild
dementia (CDR 0.5) to those with mild dementia (CDR 1) there were no
signiﬁcant effects, although gender, MCBP, and DWMH demonstrated
modest trends.
As WMH are thought to be vascular in nature (Breteler et al., 1994),
we additionally examined the initial models predicting dementia status
with MCBP and measures of WMH while including a history of hyper-
tension, or an aggregate vascular risk factor in the model. A history of
hypertension was not signiﬁcant in either model (PVWMH or DWMH,
see Table 5) and only slightly lowered the contributions of WMH to
themodel, but such effects were still signiﬁcant. The aggregate vascular
risk factor was signiﬁcant in both models, but again the effects on the
WMH scores were minor (Table 6).Table 4
Effects of deepwhitematter hyperintensities. For all comparisons cognitively normal indi-
viduals are used as the reference group.
B Std. error Sig. Exp(B)
CDR 0 vs. 0.5 Intercept −10.43 1.71 .000
Age .10 .02 .000 1.10
Gender 1.07 .35 .002 2.93
MCBP 1.18 .26 .00001 3.24
DWMH .35 .21 .093 1.41
CDR 0 vs. 1 Intercept −14.36 3.71 .0005
Age .09 .05 .075 1.09
Gender 3.28 1.17 .005 26.66
MCBP 1.99 .51 .0005 7.32
DWMH 1.01 .47 .031 2.75
CDR 0.5 vs. 1 Intercept −3.93 3.74 .293
Age −.01 .05 .807 .99
Gender 2.21 1.17 .060 9.11
MCBP .81 .51 .110 2.26
DWMH .67 .47 .156 1.95
MCBP = mean cortical binding potential; DWMH= deep white matter hyperintensity;
Exp(B) = exponentiation of B coefﬁcient, or the odds ratio.4. Discussion
In the current analyses we examined whether measures of amyloid
deposition andwhite matter damage predict cognitive impairment. We
found that both amyloid burden, estimated by PiB MCBP, as well as
measures of WMH independently discriminate between cognitively
normal individuals and those with very mild or mild dementia. The ef-
fects were similar when considering either periventricular or deep
white matter lesions. This is unsurprising as the correlation between
ratings of DWMH and PVWMH lesions was .58 (p b 0.000001).
The Fazekas visual rating of white matter disease was associated
with a greater risk of AD. This can clearly been seen in how the distribu-
tion of the Fazekas scores shifts across groups in Fig. 2. Individuals who
are cognitively normal have highly right skewed distributions, with the
vast majority of individuals having no observable whitematter damage.
As dementia severity increases, the scores become more and more left
skewed as higher proportions of the population accrue white matter
damage. Although the graphs in Fig. 2 suggest differences between
CDR=0.5 and 1 individuals the effects were not statistically signiﬁcant.
This is most likely due to the modest sample size of mildly demented
subjects (CDR = 1, n = 11). Alternatively these markers may possess
nonlinear trajectories that do not signiﬁcantly differ across graded
levels of dementia severity.
In our cohort all of the individuals with a CDR = 1 had a primary
clinical diagnosis of dementia of the Alzheimer3s type at baseline. Of
the 51 individuals with a CDR rating of 0.5, 21 had a DAT diagnosis at
baseline and 14 received a diagnosis at a later clinical point. Overall
75% of individuals in the study received a clinical diagnosis of DAT.
Along with the high levels of amyloid deposition, this would suggest
that the majority of the impaired cohort are representative of an AD
trajectory. There were no signiﬁcant differences in age, gender compo-
sition, or severity of white matter damage between those with and
without an AD diagnosis. This suggests that the white matter effectsTable 6
Logistic regression examining the effects of white matter hyperintensities on cognition
controlling for an aggregate vascular risk factor.
B Std. error Sig. Exp(B)
CDR 0 vs. CDR N 0 Intercept −9.25 1.75 .00001
Age .07 .02 .001 1.07
Gender 1.13 .35 .001 3.11
Vascular risk .34 .14 .012 1.41
MCBP 1.45 .27 .00001 4.26
PVWMH .67 .19 .001 1.96
CDR 0 vs. CDR N 0 Intercept −10.55 1.70 .00001
Age .09 .02 .001 1.09
Gender 1.16 .34 .001 3.19
Vascular risk .35 .13 .008 1.42
MCBP 1.45 .26 .00001 4.28
DWMH .37 .20 .061 1.45
251B.A. Gordon et al. / NeuroImage: Clinical 8 (2015) 246–252are not being driven by a small subsample of individuals who are de-
mented but are not on an AD trajectory.
Many healthy older adults show elevated levels of amyloid without
signiﬁcant cognitive impairment (Arriagada et al., 1992). Additionally
there are numerous risk factors for a clinical diagnosis of AD including
a family history of AD (Breitner et al., 1988), the APOE ε4 genotype
(Corder et al., 1993), head trauma (Mortimer et al., 1985), and diabetes
(Luchsinger et al., 2001). The additive effects in our study of WHM and
PiB deposition are consistent with a broader view of AD that suggests
that multiple factors can inﬂuence substantial cognitive decline and de-
mentia. For example after head trauma there is a deposition of Aβ in the
cortex, and this deposition is increased in individuals with the APOE ε4
genotype (Mayeux et al., 1995).
The results of our analyses are consistent with a large body of prior
work linking white matter damage with impaired cognition (Bozzali
et al., 2002; Debette et al., 2010; Frisoni et al., 2007; Head et al., 2004;
Prins et al., 2004). An increased prevalence of white matter damage is
thought to bemainly vascular in nature, as hypertension, stroke, and di-
abetes all lead to increases inwhitematter lesions (Debette andMarkus,
2010; Pico et al., 2002). In the current work there weremodest correla-
tions (rs b .2) between measures of vascular health and WMH. Further
an aggregate measure of vascular risk was itself predictive of dementia
status above the effects of amyloid deposition and WMH. However
measures of WMHwere still predictive of dementia status after includ-
ing vascular risk as a covariate. Thismay be due to the fact that ourmea-
sures of vascular health are imperfect as they are derived from self-
report and do not account for medication usage.
Although the examinations presented here indicated unique statisti-
cal effects of age, MCBP, and WMH this does not necessarily mean that
the biological processes these values represent are truly orthogonal pro-
cesses. One of the greatest challenges facing ongoing studies of AD is
how to tease apart the contributions of comorbid pathologies. Large co-
hort studies are just now reaching the point to investigate modiﬁers
(e.g. cardiovascular health, stroke, diabetes, head trauma) of longitudi-
nal AD biomarker trajectories. Autosomal dominant AD also presents
another potential avenue to disentangle such questions. Individuals
suffering from autosomal dominant AD become demented at a much
earlier age than those with sporadic AD. Due to the young age of onset
of clinical symptoms, this population may provide greater insight into
the relationship between white matter damage and AD removed from
age-related comorbidities such as cardiovascular health.
The current work demonstrates a signiﬁcant relationship between
both levels of amyloid deposition andwhitematter damage on cognition.
However the current analyses are not without limitations. The sample
contained only a modest number of mildly demented individuals
(CDR = 1), limiting our ability to detect differences with progressive in-
creases in dementia severity. As commonly done in the literature, our vi-
sual ratingsweremade on T2-weighted sequences, althoughmore precise
measures may have been obtained using a more optimal sequence (e.g.
FLAIR). Additionally, although visual ratings of WMH such as the Fazekas
rating scale have a clear utility, they do not provide theﬁne-grained detail
as would be obtained from a quantiﬁcation of WMH volume. Finally,
although the Fazekas scale separates lesions into periventricular
and deep white matter scores, three-dimensional renderings of typ-
ical lesions suggest that such lesions are part of the same process rather
than representing disparate effects.
5. Conclusions
The work presented here demonstrated the detrimental inﬂuences
of advancing age, amyloid deposition in the brain, and white matter
damage. These factors independently discriminated healthy controls
from very mildly and mildly demented individuals. From a clinical
standpoint, this suggests that easily available radiological measures of
white matter health could be an asset in disease diagnosis in addition
to psychometric testing and AD biomarkers such as amyloid imaging.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nicl.2015.04.017.
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